Online inquiry

IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14461MR)

This product GTTS-WQ14461MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14461MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15396MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ9707MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ1020MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ7017MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ15935MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ2465MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ13913MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ11559MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW